• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke.
Conclusions: CR and END are fairly common after acute IS. CR is associated with higher risk of END. Clopidogrel plus aspirin combination therapy provides greater inhibition of platelet aggregation, and may afford protection against END. PMID: 29731992 [PubMed]
Source: Oncotarget - May 9, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
Conclusions: Among IS patients treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had a significantly higher rate of adverse vascular events than did noncarriers. It should avoid prescribing clopidogrel to these patients with known CYP2C19 polymorphisms. PMID: 29707143 [PubMed]
Source: Oncotarget - May 2, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Aspirin for Primary Prevention.
Abstract Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer. Aspirin increases the risk of gastrointestinal and intracranial bleeding. The best available evidence supports initiating aspirin in select populations. In 2016, the US Preventive Services Task Force recommended initiating aspirin for the primary prevention of both cardiovascular disease and colorectal cancer among adults ages 50 to 59 who are at increased risk for cardiovascular disease. Adults 60 to 69 who are at increased cardiovascular disease risk may also benefit. There remains considerable unce...
Source: Clinical Colorectal Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Richman IB, Owens DK Tags: Med Clin North Am Source Type: research

Use and Misuse of Aspirin in Primary Cardiovascular Prevention.
Abstract The use of low-dose aspirin in primary prevention of cardiovascular (CV) events in healthy or apparently healthy people is a widely debated topic. Many arguments indicate that "primary prevention" is only a conventional definition and that the transition from primary to secondary prevention represents a continuum of increasing levels of CV risk. Although there are no direct proofs of a different efficacy of aspirin at different CV risk levels, in low-risk populations aspirin will appear to be less efficient. In fact, the lower number of events occurring in patients at low risk yields lower absolute number...
Source: Clinical Colorectal Cancer - May 6, 2017 Category: Cancer & Oncology Authors: Coccheri S Tags: Clin Med Insights Cardiol Source Type: research

Task Force Releases Recommendations on Aspirin to Prevent Colon Cancer, Heart Disease
By Stacy SimonRESOURCES: Aspirin and Cancer Prevention: What the Research Really Shows The United States Preventive Services Task Force (USPSTF) has published new recommendations about aspirin to help prevent cardiovascular disease (heart attacks and strokes) and colorectal cancer (commonly called colon cancer).The USPSTF says people who are ages 50-59 years, who have at least a 10% risk of developing cardiovascular disease within the next 10 years, and who have no increased risk for bleeding should take low-dose aspirin regularly to help prevent heart attack, stroke, and colon cancer. Candidates should also have a l...
Source: American Cancer Society :: News and Features - April 11, 2016 Category: Cancer & Oncology Tags: Colon/Rectum Cancer Source Type: news

USPSTF publishes recommendation on taking aspirin to prevent heart attack, stroke, and colorectal cancer
(American College of Physicians) The US Preventive Services Task Force recommends that people who are 50-69 years old, have increased risk of cardiovascular disease (CVD), and who are not at increased risk for bleeding, consider taking aspirin for primary prevention of CVD and colorectal cancer. The full recommendation and evidence reviews are published in Annals of Internal Medicine.
Source: EurekAlert! - Cancer - April 11, 2016 Category: Cancer & Oncology Source Type: news

Survey shows half of older adults in US now taking aspirin
(Oregon State University) A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke. The findings suggest that tens of millions of Americans have reviewed the issues involved, often discussed it with their doctors, say they know what they are doing -- and decided to use aspirin.
Source: EurekAlert! - Cancer - April 16, 2015 Category: Cancer & Oncology Source Type: news

Estimates of benefits and harms of prophylactic use of aspirin in the general population
Conclusions Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit–harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening–eradication before starting aspirin prophylaxis.
Source: Annals of Oncology - December 17, 2014 Category: Cancer & Oncology Authors: Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., Law, M., Meyskens, F., Rothwell, P. M., Senn, H. J., Umar, A. Tags: reviews Source Type: research